Solventum has raised its full-year adjusted earnings forecast after a third quarter shaped by the expected reversal of ERP-related advance orders. The healthcare technology company also completed its major system cutovers and reported strong growth in Advanced Wound Care.
- Adjusted EPS guidance increased to US$7.20-US$7.30
- Third-quarter organic sales fell 2.8% after ERP-related order timing effects
- GAAP diluted EPS was a loss of US$0.07, versus adjusted EPS of US$1.45
- Advanced Wound Care sales rose 7.2% organically
- About 90% of 3M transition service agreements have been exited
ERP timing weighs on sales, but earnings guidance rises
The quarter that was supposed to absorb the disruption from Solventum Corporation (NYSE:SOLV)'s biggest ERP cutover instead produced a result ahead of management's expectations, prompting the company to lift its full-year adjusted earnings outlook. Third-quarter sales fell 7.0% to US$1.949 billion, while organic sales declined 2.8%, but Solventum now expects full-year organic growth towards the high end of its 2.5% to 3.0% range and has increased adjusted diluted EPS guidance to US$7.20-US$7.30 from US$7.10-US$7.20.
Management attributed 630 basis points of the quarterly organic sales decline to the expected reversal of advance orders placed in the previous quarter ahead of the ERP cutover. The cutovers are now complete, and Solventum said it has exited about 90% of its transition service agreements with former parent 3M. That removes a significant execution milestone, although the next quarter should show whether the sales timing effect reverses as expected rather than simply shifting revenue between periods.
GAAP loss masks a smaller adjusted decline
Solventum reported a GAAP diluted loss of US$0.07 per share, compared with earnings of US$7.22 a year earlier. The comparison is distorted by the prior-year period's US$1.518 billion gain on the sale of the Purification and Filtration business, as well as current-year restructuring, separation, amortisation, litigation and acquisition-related charges.
On the company's non-GAAP measure, adjusted diluted EPS was US$1.45, down 3.6% from US$1.50. Adjusted operating margin declined to 19.9% from 20.6%, with portfolio optimisation, product mix and savings programmes supporting gross margin while inflation, tariffs and the ERP-related order reversal worked in the other direction. Nine-month adjusted EPS was US$5.48, up 20.9%, but GAAP net income for the same period fell to US$93 million from US$1.493 billion.
Wound care leads uneven segment performance
Advanced Wound Care was the clearest growth engine in the quarter, with sales of US$528 million and organic growth of 7.2%. MedSurg sales were broadly flat on a reported basis at US$1.211 billion, although organic sales fell 2.8%; Dental Solutions declined 7.4% organically to US$317 million. Health Information Systems grew 4.4% organically to US$356 million and delivered a 41.7% segment operating margin.
The product pipeline also produced a regulatory milestone: the US Food and Drug Administration granted 510(k) clearance for the combined use of Restrata and V.A.C. Therapy. The clearance brings two wound-care technologies together within Solventum's portfolio, but the filing does not quantify the commercial opportunity or indicate how quickly adoption may build.
Cash flow improves, but full-year conversion remains ahead
Quarterly operating cash flow rose to US$177 million from US$75 million, while free cash flow, a non-GAAP measure, reached US$97 million compared with negative US$22 million a year earlier. Solventum said the result was helped by an IEEPA tariff refund. For the first nine months, however, free cash flow remained negative at US$32 million, and the company is still guiding to US$200 million-US$300 million for the full year.
That makes the final quarter important beyond the headline EPS upgrade. Solventum must demonstrate that ERP normalisation, restructuring savings and segment growth can translate into cash, while its planned separation of Health Information Systems introduces another source of execution activity. The raised outlook is encouraging, but much of the investment case now rests on the company converting a cleaner standalone platform into more consistent sales and cash generation.
Bottom Line?
The ERP cutover is complete and the earnings target has moved higher, but the next proof point is whether organic growth and cash flow improve without another timing benefit or one-off refund.
Questions in the middle?
- Will the 630-basis-point ERP timing effect reverse into reported sales in the December quarter as management expects?
- Can Advanced Wound Care and Health Information Systems offset continued weakness in Dental Solutions and Infection Prevention?
- How much of the US$200 million-US$300 million free-cash-flow target will remain after restructuring and Health Information Systems separation costs?